Biohaven (BHVN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of three directors for terms expiring at the 2029 Annual Meeting: Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin.
Proposal to ratify Ernst & Young LLP as independent auditors for fiscal year 2026.
Advisory vote on the compensation of named executive officers is included.
Proxies may vote on other business that arises during the meeting or any adjournments.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Executive compensation and say-on-pay
Shareholders will cast a non-binding advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biohaven
- Net loss narrowed on lower expenses; pivotal trial results for key programs expected in H2 2026.BHVN
Q2 2026 - Net loss narrowed to $130.5 million as cash reserves exceeded $350 million, supporting clinical progress.BHVN
Q1 2026 - Director elections, auditor ratification, and Say-on-Pay headline a year of strategic execution.BHVN
Proxy Filing - First-in-class degraders, novel CNS and obesity therapies, and oncology assets advance toward pivotal trials in 2026.BHVN
44th Annual J.P. Morgan Healthcare Conference presentation - Net loss narrowed as cost optimization and capital raises support pivotal trials in 2026.BHVN
Q4 2025 - Proxy covers director elections, auditor ratification, executive pay, and governance highlights.BHVN
Proxy Filing - Definitive additional proxy materials update shareholders on voting and securities matters.BHVN
Proxy Filing - Q3 2025 saw a $173.4M net loss, major R&D cuts, and $263.8M in cash for near-term operations.BHVN
Q3 2025 - Troriluzole slowed SCA progression by up to 70% over 3 years, with robust safety and efficacy.BHVN
Study Result